Inve India ▾
ACACCENTMIC

Accent Microcell Q4 FY26 results (Jan–Mar 2026) and concall

Healthcare · Concall AI · Call held 16 May 2026

Accent Microcell delivered a strong FY26, driven by a strategic shift towards higher-value premium products and robust export growth, which now constitutes 63% of total revenue. The company achieved a 38% gross profit margin on 15,000 metric tons of sales volume. While the crucial Unit 3 Phase 1 expansion faced delays due to regulatory and environmental factors, it is now expected to commence commercial production by June 25th, 2026, with Phase 2 following in March 2027. Management anticipates significant revenue contribution and margin improvement from these new capacities, alongside efforts

You’re reading a preview. Opening the full call uses 1 concall credit.

Sign in to use your monthly call allowance.

What they filed

Q4 FY26: revenue up 51.1%, net profit up 62.5% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY24Q4 FY24Q2 FY25Q4 FY25Q2 FY26Q4 FY26
Revenue107 139 126 139 139 +30%210 +51%
EBITDA20 20 19 23 24 +20%33 +65%
Net profit14 16 16 17 18 +29%26 +63%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.